Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Precipio, Inc.PRPO · Entity 7207 | Director | January 15, 2026 | January 20, 2026 |
| Q32 Bio Inc.QTTB · Entity 5594 | Director | June 12, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 690,900 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 690,900 · Balance 690,900 |
Precipio, Inc.
Report date January 15, 2026 · Filed January 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,382 |
Reported balance
After 2026-01-15 transaction · row 1
1 source rowRow 1 · 2026-01-15 · Grant · Acquired 520 · Balance 7,382 F1: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25. |
Filing footnotes · ownership attribution and instrument terms
F1: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25.
Q32 Bio Inc.
Report date June 12, 2026 · Filed July 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11 | Direct | 10,826 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
89bio, Inc.
Report date October 30, 2025 · Filed October 31, 2025
Section 16 reporting ended · disclosed 2025-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.68 · Expires 2031-11-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2032-05-16 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-30 · Disposition to issuer · Disposed 27,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-30 · Disposition to issuer · Disposed 45,150 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-30 · Disposition to issuer · Disposed 56,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]
F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]
F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]
F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $42.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 15 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2031-01-04 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 14 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200 Underlying: Common Stock · 200 shares Expires 2030-07-02 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 13 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200 shares Expires 2030-07-02 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 375 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 12 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires 2030-01-16 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 375 | $0.00 Strike: $42.80 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 11 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires 2030-01-16 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 70 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 10 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70 Underlying: Common Stock · 70 shares Expires 2029-04-17 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70 | $0.00 Strike: $123.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 9 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70 shares Expires 2029-04-17 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 28 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 8 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28 Underlying: Common Stock · 28 shares Expires 2029-04-17 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28 | $0.00 Strike: $123.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 7 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28 shares Expires 2029-04-17 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 250 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 6 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 250 shares Expires 2029-03-18 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 250 | $0.00 Strike: $45.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 5 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2029-03-18 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 188 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 4 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188 Underlying: Common Stock · 188 shares Expires 2028-08-07 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 188 | $0.00 Strike: $129.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188 shares Expires 2028-08-07 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 75 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75 Underlying: Common Stock · 75 shares Expires 2028-08-07 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75 | $0.00 Strike: $129.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75 shares Expires 2028-08-07 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:15 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001104659-24-074810 · tm2418227-7_4seq.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-06-21 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:52 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073889 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:26 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 9,693 | $6.70 | $64,943.10 |
DisclosureSEC source: 0001104659-24-048332 · tm2412083-7_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,071 F1 · price: 9,693 shares of common stock were granted upon the close of business on April 15, 2024, as a consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors for Q1-23 to Q4-23 and Q1-24. The price reported in Column 4 is a weighted average price ranging from $5.35 to $6.74. The reporting person undertakes to provide, upon request, full information regarding the number of shares calculated at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2024 Filed Mar 28, 2024 01:28 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001213900-24-026822 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-03-24 F1 · derivative.exercise_date: The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:35 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037387 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:37 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantSeries A Convertible Preferred Stock · Derivative | 50 | $1,000.00 Strike: $10.00 | $50,000.00 |
DisclosureSEC source: 0001213900-24-015027 · ownership.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F2 · derivative.expiration_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 00:37 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | OtherCommon Stock | 5,828 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-015027 · ownership.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,828 F1 · kind: Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. F1 · price: Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration. Read SEC document |
| February 14, 2024 Filed Feb 21, 2024 22:57 UTC Amendment | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantSeries A Convertible Preferred Stock · Derivative | 50 | $1,000.00 Strike: $10.00 | $50,000.00 |
DisclosureSEC source: 0001213900-24-015876 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kathleen LaPorte Revocable Trust Disclosed balance after: 50 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F1 · derivative.expiration_date: On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date. F2 · ownership.nature: The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Kathleen Trust") and has sole voting and disposition power with respect to the shares owned by the Kathleen Trust. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:11 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 45,150 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0000950170-24-011467 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,150 Underlying: Common Stock · 45,150 shares Expires 2034-02-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:41 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 7,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-100815 · tm2326171-5_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,575 F1 · price: The 7,575 restricted shares of common stock were granted upon the close of business on September 12, 2023 and vested immediately upon issuance. The restricted shares were issued as consideration in lieu of cash payment of deferred compensation for service as a member of the Board of Directors. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 22:04 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000950170-23-033420 · ownership.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is vested in full. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 22:04 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 12,500 | $18.80 | $235,000.00 |
DisclosureSEC source: 0000950170-23-033420 · ownership.xml · nonDerivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.77 to $18.90. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2023 Filed Jul 18, 2023 22:04 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionCommon Stock | 12,500 | $2.64 | $33,000.00 |
DisclosureSEC source: 0000950170-23-033420 · ownership.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-037107 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:35 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 27,400 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0000899243-23-004800 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2033-02-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:44 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001104659-23-002766 · tm233036-5_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-06 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 18:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001209191-22-061587 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-13 F1 · derivative.exercise_date: The shares subject to this option shall be fully vested upon grant date of December 14, 2022. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:15 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-22-036079 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:06 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0000899243-22-018593 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:22 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012464 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-03-23 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 22:09 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $1.54 | Not disclosed |
DisclosureSEC source: 0001104659-22-004067 · tm222906-9_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-11 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:36 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $18.68 | $0.00 |
DisclosureSEC source: 0000899243-21-042740 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in equal installments on November 1, 2022, November 1, 2023 and November 1, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 23:28 UTC | CERO THERAPEUTICS HOLDINGS, INC. PBAX · Entity 8622 | OtherClass B Common Stock · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039932 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Phoenix Biotech Sponsor, LLC Disclosed balance after: 17,500 Underlying: Class A Common Stock · 17,500 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F2 · kind: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC, for service on the issuer's board of directors. F3 · shares: The reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose. F2 · price: Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC, for service on the issuer's board of directors. F1 · derivative.exercise_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. F1 · derivative.expiration_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:43 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.22 | Not disclosed |
DisclosureSEC source: 0001104659-21-100870 · tm2124311-7_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-08-03 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| February 09, 2021 Filed Feb 9, 2021 20:35 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 1,200 | $20.00 | $24,000.00 |
DisclosureSEC source: 0001209191-21-008756 · doc4.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-21-000964 · tm211613-5_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-01-04 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:32 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 4,000 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001104659-20-081247 · tm2024163d7_4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-07-02 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:22 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-20-005500 · tm205425-2_4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-16 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| April 17, 2019 Filed Apr 22, 2019 20:00 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 21,163 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001144204-19-020552 · tv519332_4.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,163 Underlying: Common Stock · 21,123 shares Expires 2028-08-06 F2 · derivative.exercise_date: This option shall vest as follows: shall vest in 26 equal monthly installments Read SEC document |
| April 17, 2019 Filed Apr 22, 2019 20:00 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 8,465 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001144204-19-020552 · tv519332_4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 Underlying: Common Stock · 8,465 shares Expires 2028-08-06 F1 · derivative.exercise_date: This option shall vest as follows: shall vest in 4 equal monthly installments. Read SEC document |
| March 18, 2019 Filed Mar 20, 2019 21:00 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001144204-19-015162 · tv516768_4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-18 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| August 07, 2018 Filed Aug 13, 2018 22:41 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 56,400 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0000899243-18-022168 · doc4.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,400 Underlying: Common Stock · 56,400 shares Expires 2028-08-06 F1 · derivative.exercise_date: This option shall vest as follows: shall vest in 36 equal monthly installments. Read SEC document |
| August 07, 2018 Filed Aug 13, 2018 22:41 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 22,560 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0000899243-18-022168 · doc4.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,560 Underlying: Common Stock · 22,560 shares Expires 2028-08-06 F1 · derivative.exercise_date: This option shall vest as follows: shall vest in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.